Table 1 Overall population characteristics (per patients) and comparison of hospital stays between pre- and post-intervention periods
From: Antimicrobial stewardship in high-risk febrile neutropenia patients
Patients characteristics | Pre-intervention period Jan–Oct 2018 N = 164 patients | Post-intervention period Jan–Oct 2019 N = 148 patients | p value |
|---|---|---|---|
Age (year); Median [IQR] | 60.4 [49.4–71.9] | 65.2 [54.3–72.8] | 0.049 |
Sex (female); N (%) | 78 (47.6) | 65 (43.9) | 0.60 |
Charlson comorbidity index; Median [IQR] | 2 [2–4] | 2 [2–6] | 0.54 |
Number of stays; Median [IQR] | 1 [1–2] | 1 [1–2] | 0.49 |
Hematological disease; N (%) | 0.44 | ||
Myeloma | 37 (22.6) | 45 (30.4) | |
Acute myeloid leukemia | 31 (18.9) | 32 (21.6) | |
Aggressive lymphoma | 28 (17.1) | 26 (17.6) | |
Indolent lymphoma | 20 (12.2) | 9 (6.1) | |
ALL/LBL | 18 (11) | 11 (7.4) | |
Myelodysplastic syndrome | 7 (4.3) | 9 (6.1) | |
Hodgkin lymphoma | 6 (3.7) | 4 (2.7) | |
Aplastic anemia | 5 (3) | 5 (3.4) | |
Other | 12 (7.3) | 7 (4.7) |
Hospital stays characteristics | Pre-intervention period Number of hospital stay = 273 | Post-intervention period Number of hospital stay = 217 | p-value |
|---|---|---|---|
Total number of patient-days | 3180 | 3129 | – |
Cause of hospitalization; N (%) | 0.28 | ||
Intensive or induction chemotherapy | 57 (20.9) | 38 (17.5) | |
Leukemia consolidation chemotherapy | 32 (11.7) | 27 (12.4) | |
Chemotherapy (other) | 67 (24.5) | 49 (22.6) | |
Autologous BMT | 51 (18.7) | 48 (22.1) | |
Transfusion | 9 (3.3) | 9 (4.1) | |
Palliative care | 4 (1.5) | 5 (2.4) | |
Aplasia | 1 (0.4) | 5 (2.4) | |
Antithymocyte globulin + ciclosporin | 1 (0.4) | 4 (1.8) | |
Other | 51 (18.6) | 32 (14.7) | |
Number of stays with febrile episode; N (%) | 118 (43.2) | 116 (53.5) | 0.031 |